Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 6/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30132029 | 1.00 | HTT (0.70) | HTTKCNH2KDM1ARETHRH4 | |
| Trifluoroacetic Acid SCHEMBL30274922 | 0.93 | HTT (0.63) | HTT | |
| SCHEMBL30131762 | 0.87 | HTT (0.68) | HTTKCNH2KDM1A | |
| SCHEMBL25316418 | 0.87 | HTT (0.68) | HTTKCNH2KDM1A | |
| SCHEMBL25888868 | 0.85 | HTT (0.72) | HTTKCNH2KDM1A | |
| SCHEMBL30274964 | 0.84 | HTT (0.69) | HTTKCNH2 | |
| SCHEMBL25889056 | 0.84 | HTT (0.69) | HTTKCNH2 | |
| SCHEMBL25888393 | 0.84 | HTT (0.74) | HTTKCNH2RET | |
| Hydrochloric Acid SCHEMBL30274911 | 0.84 | HTT (0.71) | HTTKCNH2KDM1A | |
| SCHEMBL25888395 | 0.84 | HTT (0.74) | HTTKCNH2RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234942-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2023-07-27 | — | — | US | claimed |
| US-20230234942-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230234942-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234942-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, CLN6 | HTT 1/4885KCNH2 2650/4885KDM1A 3101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.